In conclusion, PSMA PET provides many answers and important information for clinicians when it comes to the management of patients with prostate cancer even at low PSA values where traditional imaging modalities are completely inadequate at detecting malignant lesions. This evidence concerns the gene FOLH1 and prostate cancer.